About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 105 record(s)
Req # A-2021-002040
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-100122-522, Meeting with Mayor of Edmonton.Organization: Health Canada
September 2022
Req # A-2021-002072
Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: E2B_04921073, E2B_04852557, 000973761, E2B_04847601, E2B_04781885, 000970718, 000974497.Organization: Health Canada
September 2022
Req # A-2021-002135
Adverse Drug Reactions (ADRs) for METRONIDAZOLE, CLOPIDOGREL BISULFATE, FLUZONE QUADRIVALENT. Report numbers: E2B_04916460, E2B_04701007, E2B_04941688, 000973713.Organization: Health Canada
September 2022
Req # A-2022-000116
Adverse Drug Reactions (ADRs) for ZOPICLONE. Report numbers: E2B_05054265, E2B_05016280, E2B_04994415, 000982687, E2B_05009475.Organization: Health Canada
September 2022
Req # A-2022-000125
Adverse Drug Reactions (ADRs). Report numbers: E2B_05020387, E2B_05020361, E2B_05033004, E2B_05040674, E2B_05045847, E2B_05047185, E2B_05033059, E2B_05046682, E2B_05047050, E2B_05047112.Organization: Health Canada
September 2022
Req # A-2022-000129
Adverse Drug Reactions (ADRs). Report numbers: E2B_05040635, E2B_05032802, E2B_05045941, E2B_05032856, E2B_05041362, E2B_05047028, E2B_05041003, E2B_05041517 E2B_05020256, E2B_05027464.Organization: Health Canada
September 2022
Req # A-2022-000130
Adverse Drug Reactions (ADRs). Report numbers: E2B_04992008, E2B_05040868, E2B_05041419, E2B_05047246, E2B_05020246, E2B_05040995, E2B_05082952, E2B_05046485, E2B_05047294, E2B_05041692.Organization: Health Canada
September 2022
Req # A-2022-000191
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-117807-546.Organization: Health Canada
September 2022
Req # A-2022-000240
Adverse Drug Reactions (ADRs). Report numbers: 000985347, 000985350, E2B_05160722.Organization: Health Canada
September 2022
Req # A-2022-000265
Adverse Drug Reaction (ADR) for Ascorbic acid. Report number: 03211758.Organization: Health Canada
September 2022